enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the second quarter ended April 30, 2025, and provided a business update. “We have seen strong enrollment in the pivotal cohort of our LEGEND study,” said Ron Cooper, Chief Executive Officer of enGene. “This positions us to stay on track for our planned trial updates across all cohorts in the second